VG Life Sciences Inc. (VGLS) 0.0720 $VGLS
VG Life Sciences Granted Key Composition of Matter Patent
GlobeNewswire - Mon Mar 02, 9:07AM CST
VG Life Sciences, Inc., (OTCQB:VGLS), a biotechnology company developing therapies for autoimmune and infectious diseases, announced that the U.S. Patent and Trademark Office (USPTO) has issued an important new composition of matter patent covering methods for modulating immune system function through the targeting of CLIP.
VG Life Sciences Announces Issuance of Patent Covering Treatment of Inflammatory Bowel Disease with Clip-Inducing Agent
GlobeNewswire - Thu Jan 29, 9:04AM CST
VG Life Sciences, (VGLS), a biotechnology company developing therapies for autoimmune and infectious diseases, today announced the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8906846, covering a method of treating inflammatory bowel disease (IBD) through the administration of a CLIP-inducing agent.
VG Life Sciences Announces Issuance Of Patent Covering Treatment Of Inflammatory Bowel Disease With CLIP-Inducing Agent
PR Newswire - Thu Jan 29, 8:28AM CST
VG Life Sciences, (VGLS), a biotechnology company developing therapies for autoimmune and infectious diseases, today announced the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8906846, covering a method of treating inflammatory bowel disease (IBD) through the administration of a CLIP-inducing agent.
VGLS Q4 2014 Shareholder Update Letter
GlobeNewswire - Wed Jan 14, 9:13AM CST
VG Life Sciences Inc. releases a Q4 2014 Shareholder Update Letter:
Lung Adenocarcinoma - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/c2qszp/lung) has announced the addition of the "Lung Adenocarcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lung Adenocarcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lung Adenocarcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - Astex Pharmaceuticals - AstraZeneca - Axelar - Bayer - BioNumerik Pharmaceuticals - Boehringer Ingelheim - Genentech - Genmab - Hanmi Pharmaceuticals - Immunomedics - Medisyn Technologies - Pfizer - Sanofi - VG Life Sciences, Inc. - Vichem Chemie Research Ltd. For more information visit http://www.researchandmarkets.com/research/c2qszp/lung
IMMU: 4.14 (+0.07), AMGN: 163.38 (+1.89)
New Data Implicate Components of Adaptive Immunity in Traumatic Brain Injury
GlobeNewswire - Mon Oct 20, 8:39AM CDT
VG Life Sciences Inc., (OTCQB:VGLS) a biotechnology company, announces today that one of its scientific advisors, Dr. Richard Tobin, PhD, published data demonstrating that when there is traumatic brain injury (TBI), the body inflicts additional neural damage via the immune system. The data generated by Dr. Tobin shows immune therapy using VG Life Sciences' patented drug VG1177 can improve the condition.
VG Life Sciences Inc. Announces Upgrading to OTCQB Marketplace
GlobeNewswire - Thu Oct 16, 5:03PM CDT
VG Life Sciences Inc. (OTCQB: VGLS) is a biotechnology company focused on developing treatments for patients suffering from autoimmune and infectious diseases.
VG LIFE SCIENCES, INC. ANNOUNCES SEC FORM 10 REVIEW COMPLETE
GlobeNewswire - Tue Oct 14, 3:41PM CDT
VG Life Sciences Inc. (VGLS) is a publically traded biotechnology company focused on developing treatments for patients suffering from autoimmune and infectious diseases. VG Life Sciences is pleased to announce the Securities & Exchange Commission has completed their review of the company's Form 10 filing. The Form 10 was submitted on June 20, 2014 and provided comprehensive information about the capital structure, financial condition, history and governance of the company. A copy of the SEC letter is here.
Metastatic Ovarian Cancer Therapeutics Pipeline Review 2014 - 8 Companies and 11 Drug Profiles
M2 - Tue Sep 23, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rfq7sb/metastatic) has announced the addition of the "Metastatic Ovarian Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Millennium Pharmaceuticals, Inc. - Eisai Co., Ltd. - Northwest Biotherapeutics, Inc. - VG Life Sciences, Inc. - Immune Design Corp. - Aura Biosciences, Inc. Drug Profiles - bevacizumab - orteronel - antigen-presenting dendritic cells (living, autologous) - E-7449 - DCVax-Direct - Stem Cell Therapy for Oncology - hydroxychloroquine sorafenib tosylate - LV-305 - G-305 - Drugs for Metastatic Ovarian Cancer - SM-276001 For more information visit http://www.researchandmarkets.com/research/rfq7sb/metastatic
IMDZ: 24.65 (+0.16), NWBO: 8.30 (-0.14)
VG Life Sciences' Advisor Gives Preeclampsia Presentation at American Heart Association Conference
GlobeNewswire - Fri Sep 12, 7:42AM CDT
VG Life Sciences, (OTC Pink:VGLS) a biotechnology company, announces that one of its scientific advisors, Dr. Brett Mitchell, PhD, will give an oral presentation today on his preeclampsia research at the American Heart Association Council for High Blood Pressure Research Conference in San Francisco, California. Using pregnant mice who cannot genetically display MHC Class II invariant chain (CD74), the research showed the mice do not develop preeclampsia.
VG Life Sciences Inc. Progress Update Phase I Cancer Study
GlobeNewswire - Thu Sep 04, 7:27AM CDT
VG Life Sciences, (OTC Pink: VGLS) a biotechnology company, announces today an update to its physician-initiated IND phase I study to test safety and tolerability of its patented technology in patients with advanced stage solid tumors.
VG Life Sciences, Inc. - Product Pipeline Review - 2014
M2 - Thu Jul 24, 6:06AM CDT
Summary
VG Life Sciences, Inc. Announces Filing of Form 10 with the SEC.
GlobeNewswire - Mon Jun 23, 3:48PM CDT
VG Life Sciences, Inc. (VGLS) is a publically traded biotechnology company focused on developing treatments for patients suffering from autoimmune and infectious diseases.
Sepsis - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rc2rw6/sepsis_pipeline) has announced the addition of the "Sepsis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Sepsis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Sepsis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Sepsis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - Baxter International - Daiichi Sankyo Company - Novo Nordisk - Takeda Pharmaceutical Company - Chiesi Farmaceutici - Chong Kun Dang - Eisai - Huons - MetrioPharm - Opsona Therapeutics - Asahi Kasei - MSM Protein Technologies - VG Life Sciences - OncoImmune - Serum Institute of India - Endacea - ISU ABXIS - KAEL-GemVax - biosyn Arzneimittel - Cognosci - Navigen Pharmaceuticals - Lead Discovery Center - Immune Response BioPharma - Novadiscovery - XImmune - Adrenomed - ImmunNovative Developments - Diomune For more information visit http://www.researchandmarkets.com/research/rc...s_pipeline
NVO: 55.94 (+1.34), BAX: 70.57 (+0.42)
VG Life Sciences Granted Key Composition of Matter Patent
GlobeNewswire - Mon Mar 02, 9:07AM CST
VG Life Sciences, Inc., (OTCQB:VGLS), a biotechnology company developing therapies for autoimmune and infectious diseases, announced that the U.S. Patent and Trademark Office (USPTO) has issued an important new composition of matter patent covering methods for modulating immune system function through the targeting of CLIP.
VG Life Sciences Announces Issuance of Patent Covering Treatment of Inflammatory Bowel Disease with Clip-Inducing Agent
GlobeNewswire - Thu Jan 29, 9:04AM CST
VG Life Sciences, (VGLS), a biotechnology company developing therapies for autoimmune and infectious diseases, today announced the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8906846, covering a method of treating inflammatory bowel disease (IBD) through the administration of a CLIP-inducing agent.
VG Life Sciences Announces Issuance Of Patent Covering Treatment Of Inflammatory Bowel Disease With CLIP-Inducing Agent
PR Newswire - Thu Jan 29, 8:28AM CST
VG Life Sciences, (VGLS), a biotechnology company developing therapies for autoimmune and infectious diseases, today announced the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8906846, covering a method of treating inflammatory bowel disease (IBD) through the administration of a CLIP-inducing agent.
VGLS Q4 2014 Shareholder Update Letter
GlobeNewswire - Wed Jan 14, 9:13AM CST
VG Life Sciences Inc. releases a Q4 2014 Shareholder Update Letter:
Lung Adenocarcinoma - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/c2qszp/lung) has announced the addition of the "Lung Adenocarcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lung Adenocarcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lung Adenocarcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - Astex Pharmaceuticals - AstraZeneca - Axelar - Bayer - BioNumerik Pharmaceuticals - Boehringer Ingelheim - Genentech - Genmab - Hanmi Pharmaceuticals - Immunomedics - Medisyn Technologies - Pfizer - Sanofi - VG Life Sciences, Inc. - Vichem Chemie Research Ltd. For more information visit http://www.researchandmarkets.com/research/c2qszp/lung
IMMU: 4.14 (+0.07), AMGN: 163.38 (+1.89)
New Data Implicate Components of Adaptive Immunity in Traumatic Brain Injury
GlobeNewswire - Mon Oct 20, 8:39AM CDT
VG Life Sciences Inc., (OTCQB:VGLS) a biotechnology company, announces today that one of its scientific advisors, Dr. Richard Tobin, PhD, published data demonstrating that when there is traumatic brain injury (TBI), the body inflicts additional neural damage via the immune system. The data generated by Dr. Tobin shows immune therapy using VG Life Sciences' patented drug VG1177 can improve the condition.
VG Life Sciences Inc. Announces Upgrading to OTCQB Marketplace
GlobeNewswire - Thu Oct 16, 5:03PM CDT
VG Life Sciences Inc. (OTCQB: VGLS) is a biotechnology company focused on developing treatments for patients suffering from autoimmune and infectious diseases.
VG LIFE SCIENCES, INC. ANNOUNCES SEC FORM 10 REVIEW COMPLETE
GlobeNewswire - Tue Oct 14, 3:41PM CDT
VG Life Sciences Inc. (VGLS) is a publically traded biotechnology company focused on developing treatments for patients suffering from autoimmune and infectious diseases. VG Life Sciences is pleased to announce the Securities & Exchange Commission has completed their review of the company's Form 10 filing. The Form 10 was submitted on June 20, 2014 and provided comprehensive information about the capital structure, financial condition, history and governance of the company. A copy of the SEC letter is here.
Metastatic Ovarian Cancer Therapeutics Pipeline Review 2014 - 8 Companies and 11 Drug Profiles
M2 - Tue Sep 23, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rfq7sb/metastatic) has announced the addition of the "Metastatic Ovarian Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Millennium Pharmaceuticals, Inc. - Eisai Co., Ltd. - Northwest Biotherapeutics, Inc. - VG Life Sciences, Inc. - Immune Design Corp. - Aura Biosciences, Inc. Drug Profiles - bevacizumab - orteronel - antigen-presenting dendritic cells (living, autologous) - E-7449 - DCVax-Direct - Stem Cell Therapy for Oncology - hydroxychloroquine sorafenib tosylate - LV-305 - G-305 - Drugs for Metastatic Ovarian Cancer - SM-276001 For more information visit http://www.researchandmarkets.com/research/rfq7sb/metastatic
IMDZ: 24.65 (+0.16), NWBO: 8.30 (-0.14)
VG Life Sciences' Advisor Gives Preeclampsia Presentation at American Heart Association Conference
GlobeNewswire - Fri Sep 12, 7:42AM CDT
VG Life Sciences, (OTC Pink:VGLS) a biotechnology company, announces that one of its scientific advisors, Dr. Brett Mitchell, PhD, will give an oral presentation today on his preeclampsia research at the American Heart Association Council for High Blood Pressure Research Conference in San Francisco, California. Using pregnant mice who cannot genetically display MHC Class II invariant chain (CD74), the research showed the mice do not develop preeclampsia.
VG Life Sciences Inc. Progress Update Phase I Cancer Study
GlobeNewswire - Thu Sep 04, 7:27AM CDT
VG Life Sciences, (OTC Pink: VGLS) a biotechnology company, announces today an update to its physician-initiated IND phase I study to test safety and tolerability of its patented technology in patients with advanced stage solid tumors.
VG Life Sciences, Inc. - Product Pipeline Review - 2014
M2 - Thu Jul 24, 6:06AM CDT
Summary
VG Life Sciences, Inc. Announces Filing of Form 10 with the SEC.
GlobeNewswire - Mon Jun 23, 3:48PM CDT
VG Life Sciences, Inc. (VGLS) is a publically traded biotechnology company focused on developing treatments for patients suffering from autoimmune and infectious diseases.
Sepsis - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rc2rw6/sepsis_pipeline) has announced the addition of the "Sepsis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Sepsis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Sepsis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Sepsis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - Baxter International - Daiichi Sankyo Company - Novo Nordisk - Takeda Pharmaceutical Company - Chiesi Farmaceutici - Chong Kun Dang - Eisai - Huons - MetrioPharm - Opsona Therapeutics - Asahi Kasei - MSM Protein Technologies - VG Life Sciences - OncoImmune - Serum Institute of India - Endacea - ISU ABXIS - KAEL-GemVax - biosyn Arzneimittel - Cognosci - Navigen Pharmaceuticals - Lead Discovery Center - Immune Response BioPharma - Novadiscovery - XImmune - Adrenomed - ImmunNovative Developments - Diomune For more information visit http://www.researchandmarkets.com/research/rc...s_pipeline
NVO: 55.94 (+1.34), BAX: 70.57 (+0.42)
